Carmen
De Mendoza Fernandez
Investigadora en el periodo 2019-2022
Inmaculada
Jiménez Nácher
Publicaciones en las que colabora con Inmaculada Jiménez Nácher (10)
2009
-
Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients
Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 10, pp. 4153-4158
2008
-
Association between tipranavir plasma levels and virological response in HIV-infected patients
AIDS Research and Human Retroviruses, Vol. 24, Núm. 3, pp. 389-391
-
Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir
Clinical Infectious Diseases, Vol. 46, Núm. 11, pp. 1782-1785
-
Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements
Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 816-822
2007
-
Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients
AIDS Research and Human Retroviruses, Vol. 23, Núm. 7, pp. 879-885
-
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study
AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241
2005
-
Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity
HIV Clinical Trials, Vol. 6, Núm. 4, pp. 197-202
2003
-
Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure
AIDS Research and Human Retroviruses, Vol. 19, Núm. 6, pp. 457-459
-
Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations
AIDS, Vol. 17, Núm. 3, pp. 442-444
2002
-
Salvage treatment with lopinavir.ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families
HIV Clinical Trials, Vol. 3, Núm. 4, pp. 304-309